Mezzasalma Advisors LLC Has $2.44 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mezzasalma Advisors LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 2,533 shares of the biopharmaceutical company’s stock after purchasing an additional 33 shares during the quarter. Regeneron Pharmaceuticals comprises 1.2% of Mezzasalma Advisors LLC’s holdings, making the stock its 19th biggest position. Mezzasalma Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,438,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of REGN. West Paces Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the period. Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $31,000. MCF Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares during the period. Criterion Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $37,000. Finally, Bruce G. Allen Investments LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $40,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Bank of America upped their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. JPMorgan Chase & Co. upped their price target on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Monday, June 17th. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target for the company. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,027.55.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the sale, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the sale, the executive vice president now directly owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold 63,208 shares of company stock worth $62,514,142 in the last 90 days. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN traded down $20.57 during trading hours on Thursday, reaching $1,024.09. The company’s stock had a trading volume of 378,341 shares, compared to its average volume of 459,242. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The firm has a market cap of $112.84 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 2.16 and a beta of 0.13. The company’s 50-day moving average is $992.50 and its 200-day moving average is $954.60. Regeneron Pharmaceuticals, Inc. has a 52 week low of $688.52 and a 52 week high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.